Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

2.15
-0.1400-6.11%
Pre-market: 2.11-0.0400-1.86%05:47 EDT
Volume:863.01K
Turnover:1.91M
Market Cap:258.00M
PE:-2.04
High:2.30
Open:2.28
Low:2.14
Close:2.29
52wk High:3.23
52wk Low:0.9500
Shares:120.00M
Float Shares:104.94M
Volume Ratio:0.61
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0528
EPS(LYR):-1.1500
ROE:-60.75%
ROA:-26.22%
PB:1.68
PE(LYR):-1.87

Loading ...

Fate Therapeutics Reports New Employee Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Oct 02

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Oct 02

Fate Therapeutics (FATE) Securities Case Faces Another Motion to Dismiss After 2025 Dismissal Order

TIPRANKS
·
Oct 02

Fate Therapeutics to Join Jefferies, Piper Sandler Investor Healthcare Conferences

Reuters
·
Oct 01

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

GlobeNewswire
·
Oct 01

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Sep 25

Fate Therapeutics - Receives $15 Mln Award for Phase 2 FT819 Trial in Lupus Nephritis

THOMSON REUTERS
·
Sep 25

Fate Therapeutics Wins $15 Million CIRM Grant for FT819 Lupus Nephritis Phase 2 Trial

Reuters
·
Sep 25

Fate Therapeutics Launches Phase 1/2 Complete Trial of FT839 Dual-CAR T Therapy in Rheumatoid Arthritis

Reuters
·
Sep 16

Fate Therapeutics announces clinical data from FT819 study

TIPRANKS
·
Sep 09

Fate Therapeutics Presents Phase 1 Data for Off-the-Shelf CAR-T FT819 in Systemic Lupus Erythematosus at CCR-West 2026

Reuters
·
Sep 09

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

GlobeNewswire
·
Sep 09

Fate Therapeutics Joins Cantor Global Healthcare Conference Fireside Chat on FT819 Autoimmune CAR-T Program

Reuters
·
Sep 03

Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial

TIPRANKS
·
Sep 03

Fate Therapeutics intiates first patient in RECLAIM-LN trial

TIPRANKS
·
Aug 16

Fate Therapeutics Price Target Maintained with a $7.00/Share by Wedbush

Dow Jones
·
Aug 14

Fate Therapeutics - Patients to Receive Single 900 Mln-Cell Dose of Ft819; Primary Endpoint at Week 26

THOMSON REUTERS
·
Aug 14

Fate Therapeutics Initiates Potentially Registrational Reclaim-Ln Clinical Trial of FT819 for the Treatment of Lupus Nephritis

THOMSON REUTERS
·
Aug 14

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

GlobeNewswire
·
Aug 14

Equillium Q2 Post Narrower Net Loss than Expected; Starts R&D Initiatives

Reuters
·
Aug 14